[Long-term results of chemoembolization of primary liver cancer with epirubicin-lipiodol].
This pilot study deals with the long-term results from lipiodol-epirubicin chemo-embolisation in 25 patients with hepatocellular or cholangiocellular carcinomas. In a three-and-a-half year follow-up period 16 of these 25 patients died, maximum survival time being 28.4 months. Survival varied from 9.2 to 28.4 months compared with a survival time of 2-8 months in untreated patients. In this case hypervascular tumours have a better prognosis than the rarer hypovascular tumours due to the improved deposition and activity of the chemotherapeutic agent inside the tumour itself.
Abteilung für Radiologische Diagnostik, Universität Tübingen.
J
J
Pirschel
W
W
Lauchart
D002759:Adenoma, Bile Duct / Q000401:mortality / Q000628:therapy*; D001650:Bile Duct Neoplasms / Q000401:mortality / Q000628:therapy*; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D015251:Epirubicin / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007459:Iodized Oil / Q000008:administration & dosage*; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000628:therapy; D010865:Pilot Projects
D015251:Epirubicin; D007459:Iodized Oil